163 related articles for article (PubMed ID: 28697993)
21. Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model.
Yisireyili M; Takeshita K; Hayashi M; Wu H; Uchida Y; Yamamoto K; Kikuchi R; Hao CN; Nakayama T; Cheng XW; Matsushita T; Nakamura S; Murohara T
Psychoneuroendocrinology; 2016 Nov; 73():186-195. PubMed ID: 27509090
[TBL] [Abstract][Full Text] [Related]
22. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular effects of the DPP-4 inhibitors.
Jose T; Inzucchi SE
Diab Vasc Dis Res; 2012 Apr; 9(2):109-16. PubMed ID: 22337893
[TBL] [Abstract][Full Text] [Related]
24. Dipeptidyl peptidase-4 inhibition and renoprotection: the role of antifibrotic effects.
Takagaki Y; Koya D; Kanasaki K
Curr Opin Nephrol Hypertens; 2017 Jan; 26(1):56-66. PubMed ID: 27820706
[TBL] [Abstract][Full Text] [Related]
25. DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization.
Zhuge F; Ni Y; Nagashimada M; Nagata N; Xu L; Mukaida N; Kaneko S; Ota T
Diabetes; 2016 Oct; 65(10):2966-79. PubMed ID: 27445264
[TBL] [Abstract][Full Text] [Related]
26. Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice.
Marques AP; Cunha-Santos J; Leal H; Sousa-Ferreira L; Pereira de Almeida L; Cavadas C; Rosmaninho-Salgado J
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):403-413. PubMed ID: 29154902
[TBL] [Abstract][Full Text] [Related]
27. DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation.
Shinjo T; Nakatsu Y; Iwashita M; Sano T; Sakoda H; Ishihara H; Kushiyama A; Fujishiro M; Fukushima T; Tsuchiya Y; Kamata H; Nishimura F; Asano T
Am J Physiol Endocrinol Metab; 2015 Aug; 309(3):E214-23. PubMed ID: 26015438
[TBL] [Abstract][Full Text] [Related]
28. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Flatt PR; Bailey CJ; Green BD
Front Biosci; 2008 May; 13():3648-60. PubMed ID: 18508462
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of dipeptidyl peptidase-4 averts free fatty acids deposition in the hearts of oral estrogen-progestin contraceptive-induced hyperinsulinemic female rats.
Adegoke TE; Sabinari IW; Areola ED; Ajao F; Asafa OO; Soluoku TK; Bello A; Adesanmi AM; Yusuf SO; Omoleye A; Ayinla MT; Olatunji LA
Can J Physiol Pharmacol; 2021 Dec; 99(12):1316-1323. PubMed ID: 34310895
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular effects of gliptins.
Scheen AJ
Nat Rev Cardiol; 2013 Feb; 10(2):73-84. PubMed ID: 23296071
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects.
Liu Y; Hu Y; Liu T
Curr Med Chem; 2012; 19(23):3982-99. PubMed ID: 22709010
[TBL] [Abstract][Full Text] [Related]
32. Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.
Aroor AR; Habibi J; Kandikattu HK; Garro-Kacher M; Barron B; Chen D; Hayden MR; Whaley-Connell A; Bender SB; Klein T; Padilla J; Sowers JR; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2017 May; 16(1):61. PubMed ID: 28476142
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review.
Liu R; Cheng J; Wu H
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678216
[TBL] [Abstract][Full Text] [Related]
34. Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery.
Van der Veken P; Haemers A; Augustyns K
Curr Top Med Chem; 2007; 7(6):621-35. PubMed ID: 17352682
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Koska J; Sands M; Burciu C; Reaven P
Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
[TBL] [Abstract][Full Text] [Related]
36. Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review.
Turdu G; Gao H; Jiang Y; Kabas M
Future Med Chem; 2018 May; 10(10):1229-1239. PubMed ID: 29749760
[TBL] [Abstract][Full Text] [Related]
37. Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases.
Mascolo A; Rafaniello C; Sportiello L; Sessa M; Cimmaruta D; Rossi F; Capuano A
Drug Saf; 2016 May; 39(5):401-7. PubMed ID: 26873369
[TBL] [Abstract][Full Text] [Related]
38. Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective.
Kushwaha RN; Haq W; Katti SB
Curr Med Chem; 2014; 21(35):4013-45. PubMed ID: 25245373
[TBL] [Abstract][Full Text] [Related]
39. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.
Higashijima Y; Tanaka T; Yamaguchi J; Tanaka S; Nangaku M
Am J Physiol Renal Physiol; 2015 Apr; 308(8):F878-87. PubMed ID: 25656369
[TBL] [Abstract][Full Text] [Related]
40. Quercetin and Coumarin Inhibit Dipeptidyl Peptidase-IV and Exhibits Antioxidant Properties: In Silico, In Vitro, Ex Vivo.
Singh AK; Patel PK; Choudhary K; Joshi J; Yadav D; Jin JO
Biomolecules; 2020 Jan; 10(2):. PubMed ID: 32023875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
